Clinical Trials Logo

Clinical Trial Summary

The aims of this prospective study are: (1) to prospectively investigate the "true" prevalence rate, the acquisition and spontaneous clearance of H. pylori infection year by year in the population whose ages between seven and fifteen. (2) to explore the risk factors of transmission of H. pylori infection in Taiwan. (This information may be use as the guide for conduction of the national policy of public health and disease prevention.)


Clinical Trial Description

Helicobacter pylori (H. pylori), a spiral microaerophilic Gram-negative bacterium isolated in 1983, is now known as the most common gastrointestinal bacterial infection worldwide. It is the principal cause of chronic gastritis and is strongly associated with peptic ulcer disease as well as gastric cancer, including gastric lymphoma (MALT type). In developed countries, infection occurs in more than 50% of adults, whereas developing countries have infection rates reaching 90%. Among those with H. pylori infection, eradication therapy alters the natural history of recurrences with attendant morbidity and death, which previously required lifelong maintenance therapy. Perhaps the greatest concern with regard to infection with H. pylori is the increased risk for the development of gastric cancers in adulthood. This is particularly relevant because infection dating from childhood appears to enhance the risk of carcinogenesis. Because H. pylori infection is contracted primarily during the childhood years, additional epidemiological studies among pediatric populations are imperative. Therefore the validation of an inexpensive, easy-to perform, sensitive, specific, and noninvasive diagnostic test for H. pylori infection in children and adolescents is of paramount importance to enhance our presently limited understanding of H. pylori-related diseases. The optimal noninvasive tests for epidemiological research of H. pylori infection in children are still not well identified. Serologic immunoassays based on H. pylori antigens require validation in the pediatric population under evaluation. As the result of our previous study, the serological test was not sensitive enough as an epidemiology screening tool for H. pylori infection in children.The aims of this prospective study are: (1) to prospectively investigate the "true" prevalence rate, the acquisition and spontaneous clearance of H. pylori infection year by year in the population whose ages between seven and fifteen. (2) to explore the risk factors of transmission of H. pylori infection in Taiwan. (This information may be use as the guide for conduction of the national policy of public health and disease prevention.) The study population will include students of one primary school and one junior high school in Lo-Tong area. There will be 150-160 cases in each age group and will be continuously followed-up for 3 years. Blood sample will be collected from each student for the serological test. 13C-urea breath test will be performed in each student, too. The parents of students will answer a questionnaire concerning the basic epidemiological data and possible factors related to the transmission of H. pylori. The students having new acquisition of H. pylori infection in the 2nd or 3rd years' follow-up period will be collected for further investigation. These student and their family will be invited to receive panendoscopy for the evaluation of possible pathology of stomach and the isolation H. pylori strain. These H. pylori isolates will be identified by molecular genotyping for the detection of possible source of transmission in the family. All of these results will be analyzed by a SAS system. ;


Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal


Related Conditions & MeSH terms


NCT number NCT00155623
Study type Observational
Source National Taiwan University Hospital
Contact
Status Completed
Phase N/A
Start date February 2001
Completion date July 2003

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06045494 - The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21 N/A
Not yet recruiting NCT01449500 - Supplementation With L. Reuteri in H. Pylori Infected Adults N/A
Completed NCT01234389 - Immediate Detection of Helicobacter Infection With a New Electrochemical System. N/A
Not yet recruiting NCT05387005 - Screening Strategy for Gastric Cancer Prevention N/A
Not yet recruiting NCT02761005 - Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori Phase 2
Recruiting NCT03142620 - Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study Phase 3
Withdrawn NCT02090738 - A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide Phase 2
Recruiting NCT01335334 - H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study Phase 4
Recruiting NCT05544396 - Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis. N/A
Recruiting NCT04713670 - Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection Phase 4
Recruiting NCT06045832 - Oral Helicobacter Pylori Eradication N/A
Completed NCT05453994 - Bismuth for PCAB-based H. Pylori Eradication
Recruiting NCT02328131 - European Registry on the Management of Helicobacter Pylori Infection
Completed NCT00197457 - Pepsinogens as the Early Marker of H. Pylori Eradication Phase 2
Not yet recruiting NCT06412640 - Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori Phase 4
Completed NCT04036838 - ARJ C13 Urea Breath Test System Phase 2
Completed NCT06050824 - A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection Phase 4
Completed NCT02767479 - Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori Phase 3
Completed NCT01505127 - Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori Phase 3
Recruiting NCT05176821 - Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection N/A